FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207907> ?p ?o ?g. }

• W4387207907 endingPage "S151" @default.
• W4387207907 startingPage "S151" @default.
• W4387207907 abstract "NRG/RTOG 1016 was a non-inferiority phase III trial comparing radiation with cisplatin versus cetuximab monotherapy for patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC). The trial did not meet the non-inferiority criteria for overall survival (OS) and had significantly worse progression-free survival (PFS) and locoregional failure (LRF) in patients treated with cetuximab. Based on prior evidence that HNSCC patients with a germ-line mutation in KRAS (the KRAS-variant) had a positive response to radiation with cisplatin plus cetuximab without increased toxicity, samples from RTOG 1016 were used to test the protocol-specified hypothesis that KRAS-variant patients will have better outcomes when receiving IMRT + cetuximab monotherapy compared to IMRT + cisplatin.The KRAS-variant was tested in 562 samples at MiraDx, a CLIA-certified laboratory. OS, PFS, LRF, and distant metastases (DM) were as defined per the RTOG 1016 protocol, and hazard ratios (HRs) were estimated by (cause-specific) Cox models. Negative binomial regression was used to model the number of treatment-related acute and late (≤ and > 180 days from end of treatment, respectively) grade 3-5 adverse events. To assess the predictive role of the KRAS-variant, all models included KRAS, assigned treatment, and their interaction, with the interaction tested at two-sided 0.05. HRs and toxicity ratios are expressed as IMRT + cetuximab / IMRT + cisplatin.The prevalence of the KRAS-variant was 16% with similar patient and tumor characteristics and well-balanced treatment arms for variant and non-variant patients. Median follow-up was 8.6 years. There was no significant interaction between KRAS and treatment for OS (p = 0.99), PFS (p = 0.56), LRF (p = 0.09), or DM (p = 0.19) (Table 1). In KRAS-variant patients the mean acute and late toxicity ratios were 0.53 (95% CI 0.36, 0.80) and 1.62 (95% CI 0.57, 4.62). In non-variant patients, the mean acute and late toxicity ratios were 0.80 (95% CI 0.67, 0.95) and 0.55 (95% CI 0.35, 0.87), respectively. The interaction of KRAS and treatment was not significant for acute (p = 0.07) or late toxicity (p = 0.07).While this study does not directly refute prior evidence that KRAS-variant patients benefit from radiation + cisplatin and cetuximab, this study does not support the hypothesis that the KRAS-variant is a predictive biomarker of improved outcome in HPV+ oropharyngeal SCC patients treated with IMRT + cetuximab alone, and suggests that for KRAS-variant patients, potential benefits in LRF and acute toxicity with cetuximab may be offset by worse DM and worse late toxicity." @default.
• W4387207907 created "2023-09-30" @default.
• W4387207907 creator A5001478588 @default.
• W4387207907 creator A5001494802 @default.
• W4387207907 creator A5009635128 @default.
• W4387207907 creator A5011105999 @default.
• W4387207907 creator A5013860869 @default.
• W4387207907 creator A5023764421 @default.
• W4387207907 creator A5030073853 @default.
• W4387207907 creator A5030586560 @default.
• W4387207907 creator A5043045096 @default.
• W4387207907 creator A5060162833 @default.
• W4387207907 creator A5066127518 @default.
• W4387207907 creator A5068082684 @default.
• W4387207907 creator A5068906036 @default.
• W4387207907 creator A5069799062 @default.
• W4387207907 creator A5072640821 @default.
• W4387207907 creator A5074092583 @default.
• W4387207907 creator A5076901251 @default.
• W4387207907 creator A5080256711 @default.
• W4387207907 creator A5081121400 @default.
• W4387207907 creator A5082685694 @default.
• W4387207907 date "2023-10-01" @default.
• W4387207907 modified "2023-10-17" @default.
• W4387207907 title "The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer in NRG/RTOG 1016" @default.
• W4387207907 doi "https://doi.org/10.1016/j.ijrobp.2023.06.571" @default.
• W4387207907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784383" @default.
• W4387207907 hasPublicationYear "2023" @default.
• W4387207907 type Work @default.
• W4387207907 citedByCount "0" @default.
• W4387207907 crossrefType "journal-article" @default.
• W4387207907 hasAuthorship W4387207907A5001478588 @default.
• W4387207907 hasAuthorship W4387207907A5001494802 @default.
• W4387207907 hasAuthorship W4387207907A5009635128 @default.
• W4387207907 hasAuthorship W4387207907A5011105999 @default.
• W4387207907 hasAuthorship W4387207907A5013860869 @default.
• W4387207907 hasAuthorship W4387207907A5023764421 @default.
• W4387207907 hasAuthorship W4387207907A5030073853 @default.
• W4387207907 hasAuthorship W4387207907A5030586560 @default.
• W4387207907 hasAuthorship W4387207907A5043045096 @default.
• W4387207907 hasAuthorship W4387207907A5060162833 @default.
• W4387207907 hasAuthorship W4387207907A5066127518 @default.
• W4387207907 hasAuthorship W4387207907A5068082684 @default.
• W4387207907 hasAuthorship W4387207907A5068906036 @default.
• W4387207907 hasAuthorship W4387207907A5069799062 @default.
• W4387207907 hasAuthorship W4387207907A5072640821 @default.
• W4387207907 hasAuthorship W4387207907A5074092583 @default.
• W4387207907 hasAuthorship W4387207907A5076901251 @default.
• W4387207907 hasAuthorship W4387207907A5080256711 @default.
• W4387207907 hasAuthorship W4387207907A5081121400 @default.
• W4387207907 hasAuthorship W4387207907A5082685694 @default.
• W4387207907 hasConcept C121608353 @default.
• W4387207907 hasConcept C126322002 @default.
• W4387207907 hasConcept C143998085 @default.
• W4387207907 hasConcept C207103383 @default.
• W4387207907 hasConcept C2779998722 @default.
• W4387207907 hasConcept C2781187634 @default.
• W4387207907 hasConcept C44249647 @default.
• W4387207907 hasConcept C50382708 @default.
• W4387207907 hasConcept C526805850 @default.
• W4387207907 hasConcept C71924100 @default.
• W4387207907 hasConceptScore W4387207907C121608353 @default.
• W4387207907 hasConceptScore W4387207907C126322002 @default.
• W4387207907 hasConceptScore W4387207907C143998085 @default.
• W4387207907 hasConceptScore W4387207907C207103383 @default.
• W4387207907 hasConceptScore W4387207907C2779998722 @default.
• W4387207907 hasConceptScore W4387207907C2781187634 @default.
• W4387207907 hasConceptScore W4387207907C44249647 @default.
• W4387207907 hasConceptScore W4387207907C50382708 @default.
• W4387207907 hasConceptScore W4387207907C526805850 @default.
• W4387207907 hasConceptScore W4387207907C71924100 @default.
• W4387207907 hasIssue "2" @default.
• W4387207907 hasLocation W43872079071 @default.
• W4387207907 hasLocation W43872079072 @default.
• W4387207907 hasOpenAccess W4387207907 @default.
• W4387207907 hasPrimaryLocation W43872079071 @default.
• W4387207907 hasRelatedWork W2049754458 @default.
• W4387207907 hasRelatedWork W2171311886 @default.
• W4387207907 hasRelatedWork W2350493697 @default.
• W4387207907 hasRelatedWork W2435704186 @default.
• W4387207907 hasRelatedWork W2625195938 @default.
• W4387207907 hasRelatedWork W2729289325 @default.
• W4387207907 hasRelatedWork W2959605 @default.
• W4387207907 hasRelatedWork W3000288349 @default.
• W4387207907 hasRelatedWork W3026015583 @default.
• W4387207907 hasRelatedWork W3028781882 @default.
• W4387207907 hasVolume "117" @default.
• W4387207907 isParatext "false" @default.
• W4387207907 isRetracted "false" @default.
• W4387207907 workType "article" @default.